139 related articles for article (PubMed ID: 17143476)
1. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
3. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
[TBL] [Abstract][Full Text] [Related]
4. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
[TBL] [Abstract][Full Text] [Related]
6. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers.
Mizuno K; Osada H; Konishi H; Tatematsu Y; Yatabe Y; Mitsudomi T; Fujii Y; Takahashi T
Oncogene; 2002 Apr; 21(15):2328-33. PubMed ID: 11948416
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Yoshida K; Hamai Y; Suzuki T; Sanada Y; Oue N; Yasui W
Anticancer Res; 2006; 26(1A):49-54. PubMed ID: 16475678
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
9. CHFR gene is neither mutated nor hypermethylated in ovarian cancer.
Ludwig AH; Bujko M; Bidzinski M; Kupryjańczyk J
Cancer Detect Prev; 2007; 31(3):257-61. PubMed ID: 17673375
[TBL] [Abstract][Full Text] [Related]
10. CHFR-associated early G2/M checkpoint defects in breast cancer cells.
Erson AE; Petty EM
Mol Carcinog; 2004 Jan; 39(1):26-33. PubMed ID: 14694445
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
12. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes.
Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K
Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
[TBL] [Abstract][Full Text] [Related]
14. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.
Koga T; Takeshita M; Yano T; Maehara Y; Sueishi K
Int J Cancer; 2011 Mar; 128(5):1009-17. PubMed ID: 20473935
[TBL] [Abstract][Full Text] [Related]
15. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
Brandes JC; van Engeland M; Wouters KA; Weijenberg MP; Herman JG
Carcinogenesis; 2005 Jun; 26(6):1152-6. PubMed ID: 15760919
[TBL] [Abstract][Full Text] [Related]
16. RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells.
Li X; Wang X; Yang Y; Xu C; Shen H
Oncol Rep; 2012 Jul; 28(1):248-54. PubMed ID: 22469813
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of the CHFR prophase checkpoint gene in human B-cell non-Hodgkin lymphoma.
Song A; Ye J; Zhang K; Yu H; Gao Y; Wang H; Sun L; Xing X; Yang K; Zhao M
Leuk Res; 2015 May; 39(5):536-43. PubMed ID: 25798877
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
[TBL] [Abstract][Full Text] [Related]
19. Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer.
Banno K; Yanokura M; Susumu N; Kawaguchi M; Hirao N; Hirasawa A; Tsukazaki K; Aoki D
Oncol Rep; 2006 Dec; 16(6):1189-96. PubMed ID: 17089036
[TBL] [Abstract][Full Text] [Related]
20. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
